Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences

Lange, Stefan; Reinecke, Holger

doi:10.3390/cancers14020434

Cited by 9 publications

(6 citation statements)

References 84 publications

(264 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 44 CAD and cancer share numerous risk factors and cancer patients carry a higher prevalence of cardiovascular risk factors than cancer-free controls. 44 The predictive value of CAD for morbidity and mortality is well documented; however, it was not previously considered in the context of elderly patient CE. Promotion of healthy aging should be primarily based on long-life prevention of cardiovascular risk factors.…”

Section: Discussionmentioning

confidence: 99%

“…[40][41][42][43] CAD morbidity is higher in persons with cancer than in the general population. 44 CAD and cancer share numerous risk factors and cancer patients carry a higher prevalence of cardiovascular risk factors than cancer-free controls. 44 The predictive value of CAD for morbidity and mortality is well documented; however, it was not previously considered in the context of elderly patient CE.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of Adverse Outcomes in Healthy Aging Adults: Coronary Artery Disease, Lower Educational Status and Higher P-Selectin Levels

Batko-Szwaczka¹,

Francuz²,

Kosowska³

et al. 2022

CIA

View full text Add to dashboard Cite

Background Societal aging – as a global demographic phenomenon – shows no indication of abating. As a result, the problem of age-associated disability and related long-term care is emerging as a major public health challenge. It is important that methods for identifying older adults at risk of adverse outcomes are implemented early. Methods The study group consisted of 145 individuals, 44.1% women, who were randomized from community-dwelling 60–74-year-old adults. A comprehensive geriatric assessment was supplemented with Fried frailty phenotype evaluation and blood tests (including adhesion molecules, matrix metalloproteinases and neurotrophic factors). A follow-up by phone call was made for at least 3 years after the initial examination. Composite endpoint (CE) included falls, hospitalization, institutionalization and death. Results Mean study group age was 66.5 ± 4.1 years ( ) and mean number of diseases was 3.7 ± 2.2. Functional status of the subjects was good, as indicated by high Barthel Index scores of 99.1 ± 2.4, MMSE scores of 29.0 ±1.5 and no frailty case. During a three-year follow-up, 71 participants (49.0%) experienced any CE-events. The Wilcoxon-Gehan test indicates that a higher probability of three-year CE completion was associated with an age >65 years (P = 0.006), coronary artery disease (CAD) (P = 0.008), 6-Minute Walk Test <432 m (P = 0.034), serum glucose >120 mg/dL (P = 0.047), serum cortisol >10 μg/dL (P = 0.011), leptin ≥15 ng/mL (P = 0.018), P-selectin ≥23 ng/mL (P = 0.006) and GDNF ≥20 pg/mL (P = 0.004). CAD (OR = 3.64, 95% CI = 1.53−8.69, P = 0.004), educational status (OR = 0.87, 95% CI = 0.77−0.98, P = 0.022) and P-selectin levels (OR = 1.07, 95% CI = 1.02−1.13, P = 0.013) were independent measures predicting three-year CE occurrence in multivariate logistic regression analysis adjusted for clinical and functional measures, and blood tests. Conclusion Coronary artery disease, poorer lower educational status and higher P-selectin levels were predictive of adverse outcomes in the community-dwelling healthy-aging early-old adults during three-year follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Predictors of Adverse Outcomes in Healthy Aging Adults: Coronary Artery Disease, Lower Educational Status and Higher P-Selectin Levels

Batko-Szwaczka¹,

Francuz²,

Kosowska³

et al. 2022

CIA

View full text Add to dashboard Cite

show abstract

“…Myocardial infarction and coronary heart disease prevalence is high in cancer [46]. The uppermost prevalence was reported during the first 6-12 months after cancer diagnosis [47][48][49], and the risk remains high even after 10 years [49]. Arterial thrombosis, along with the creation of microthrombi, usually begins when lipid plaques build up in the arterial walls, triggering the activation of platelets and inflammatory cells, as in coronary heart disease [50].…”

Section: Pathophysiology Of Vtementioning

confidence: 99%

Updated review on malignancy-associated venous thromboembolism: Pathogenesis and comparison between various therapeutic modalities

Habas,

Rayani

et al. 2024

Yemen J Med

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is one of the life-threatening complications in cancer patients, the incidence of which is affected by the patient and malignancy-related variables. Location, type, therapeutic route, stage, grade, and non-supportive treatment of the cancer are the most important VTE risk factors. Patient age, ethnicity, and concomitant genetic or acquired comorbidities or thrombophilias are known risk factors for VTE in cancer. All high-risk cancer patients admitted to hospitals or treated as outpatients should receive VTE prophylaxis. Low molecular weight heparin is the main treatment for active malignant VTE. Vitamin K antagonists and non-Vitamin K-dependent oral anticoagulants are used in stable, non-bleeding cancer patients. Anticoagulation should be continued until the cancer is treated or at least controlled. Over the past two decades, randomized clinical and observational trials have improved the pathogenesis and therapeutic knowledge of VTE, but many challenges remain. The lack of an optimal primary prophylaxis method for inpatients and outpatients in oncology and the care of cancer-associated VTE in standard and high-bleeding risk groups are examples for which more clinical research on cancer-associated thrombosis is necessary to address these issues. In this review, we describe the pathogenesis, factors that increase the risk of VTE, and the comparison between the effectiveness of available anticoagulants in the treatment and prevention of VTE in cancer patients.

show abstract

“…Recent studies showed that hematologic diseases can be treated well with a variety of modern therapies [8], but when combined with myocardial infarction (MI), they lead to an excess mortality [9][10][11]. However, there are few retrospective studies in the literature that have specifically examined HM and CAD [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Survival of Patients with Acute Coronary Syndrome and Hematologic Malignancies—A Real-World Analysis

Lange,

Schliemann,

Engelbertz

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Background: The impact of the encounter between coronary heart disease (CHD) and cancer, and in particular hematologic malignancies (HM), remains poorly understood. Objective: The aim of this analysis was to clarify how HM affects the prognosis of acute coronary syndrome (ACS). We analyzed German health insurance data from 11 regional Ortskrankenkassen (AOK) of patients hospitalized for ACS between January 2010 and December 2018, matched by age, sex and all comorbidities for short- and long-term survival and major adverse cardiac events (MACE). Results: Of 439,716 patients with ACS, 2104 (0.5%) also had an HM. Myelodysplastic/myeloproliferative disorders (27.7%), lymphocytic leukemias (24.8%), and multiple myeloma (22.4%) predominated. These patients were about 6 years older (78 vs. 72 years *). They had an ST-segment elevation myocardial infarction (STEMI, 18.2 vs. 34.9% *) less often and more often had a non-STEMI (NSTEMI, 81.8 vs. 65.1% *). With the exception of dyslipidemia, these patients had more concomitant and previous cardiovascular disease and a worse NYHA stage. They were less likely to undergo coronary angiography (65.3 vs. 71.6% *) and percutaneous coronary intervention (PCI, 44.3 vs. 52.0% *), although the number of bleeding events was not relevantly increased (p = 0.22). After adjustment for the patients’ risk profile, the HM was associated with reduced long-term survival. However, this was not true for short-term survival. Here, there was no difference in the STEMI patients, * p < 0.001. Conclusion: Survival in ACS and HM is significantly lower, possibly due to the avoidance of PCI because of a perceived increased risk of bleeding.

show abstract

Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences

Cited by 9 publications

References 84 publications

Predictors of Adverse Outcomes in Healthy Aging Adults: Coronary Artery Disease, Lower Educational Status and Higher P-Selectin Levels

Predictors of Adverse Outcomes in Healthy Aging Adults: Coronary Artery Disease, Lower Educational Status and Higher P-Selectin Levels

Updated review on malignancy-associated venous thromboembolism: Pathogenesis and comparison between various therapeutic modalities

Survival of Patients with Acute Coronary Syndrome and Hematologic Malignancies—A Real-World Analysis

Contact Info

Product

Resources

About